American Academy of Allergy, Asthma, and Immunology Virtual Annual Meeting (AAAAI 2022)

26 February 2022 - 28 February 2022

Anaphylaxis after COVID mRNA vaccination relatively rare

06 Apr 2022 by

Anaphylactic reactions warranting treatment after receipt of COVID-19 mRNA vaccinations appear to be relatively rare, according to a US study presented at AAAAI 2022.

06 Apr 2022

Benralizumab reduces asthma exacerbation rates in real-world setting

31 Mar 2022 by

Treatment with benralizumab significantly reduces exacerbation rates in patients with asthma in a real-world setting, according to the ZEPHYR 2 study presented at AAAAI 2022.

31 Mar 2022

Tezepelumab cuts asthma attacks in patients with severe asthma across seasons

30 Mar 2022 by

Not only does tezepelumab reduce asthma symptomatic days, it prevents asthma exacerbations across all seasons in adolescents and adults with severe, uncontrolled asthma, according to the prespecified exploratory analyses of the NAVIGATOR trial presented at AAAAI 2022.

30 Mar 2022

Abrocitinib effectively manages AD flares

21 Mar 2022 by

Rescue therapy using the Janus kinase 1 inhibitor abrocitinib combined with topical medicated therapy recaptured efficacy responses and had a favourable safety profile in individuals with moderate-to-severe atopic dermatitis (AD) who experienced flare during the maintenance period of the phase III randomized-withdrawal JADE REGIMEN trial.

21 Mar 2022

COVID-19 vax tolerated even in people with mast cell activation syndrome

18 Mar 2022 by

COVID-19 vaccination is generally well tolerated, even in people with mast cell activation syndrome (MCAS) —among whom vaccine hesitancy is high, according to studies presented at AAAAI 2022.

18 Mar 2022

Budesonide reduces nasal congestion symptoms in adults with rhinitis

17 Mar 2022 by

Treatment with intranasal budesonide significantly reduces nasal congestion symptoms in adults with rhinitis triggered or worsened by airborne pollution, according to a study presented at AAAAI 2022.

17 Mar 2022

EMPOWER reflects efficacy, safety of lanadelumab for HAE in real world

07 Mar 2022 by

Real-world interim findings from the phase IV, noninterventional EMPOWER trial showed reduced attack rates and improved quality of life (QoL) in individuals who received lanadelumab for the treatment of hereditary angioedema (HAE).

07 Mar 2022

Ligelizumab improves symptoms, QoL in patients with urticaria

02 Mar 2022 by

In patients with chronic spontaneous urticaria (CSU) who remained symptomatic despite treatment, the monoclonal anti-immunoglobulin E antibody ligelizumab improved symptom control regardless of BHRA* status, as well as dermatology quality of life (QoL) regardless of angioedema status, findings from a phase IIb study have shown.

02 Mar 2022